IDL Diagnostics AB (publ) (STO:IDLDX)
0.4890
-0.0010 (-0.20%)
Jun 5, 2026, 5:24 PM CET
IDL Diagnostics AB Revenue
IDL Diagnostics AB had revenue of 16.74M SEK in the quarter ending March 31, 2026, with 9.34% growth. This brings the company's revenue in the last twelve months to 54.54M, down -9.01% year-over-year. In the year 2025, IDL Diagnostics AB had annual revenue of 53.11M, down -7.54%.
Revenue (ttm)
54.54M
Revenue Growth
-9.01%
P/S Ratio
2.07
Revenue / Employee
2.18M
Employees
25
Market Cap
112.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.11M | -4.33M | -7.54% |
| Dec 31, 2024 | 57.44M | 14.40M | 33.45% |
| Dec 31, 2023 | 43.04M | 6.05M | 16.37% |
| Dec 31, 2022 | 36.99M | 24.99M | 208.32% |
| Dec 31, 2021 | 12.00M | 11.91M | 14,180.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 34.09B |
| Swedish Orphan Biovitrum AB | 28.96B |
| Sectra AB | 3.64B |
| Camurus AB | 2.24B |
| Boule Diagnostics AB | 478.39M |
| Arcoma AB | 127.06M |
| IRLAB Therapeutics AB | 92.46M |
| Clinical Laserthermia Systems AB | 14.27M |
IDL Diagnostics AB News
- 25 days ago - IDL Diagnostics AB Quarterly report: Q1 2026 - Filings
- 3 months ago - IDL Diagnostics AB Quarterly report: Q4 2025 - Filings
- 3 months ago - IDL Diagnostics AB Annual report: Q4 2025 - Filings
- 7 months ago - IDL Diagnostics AB Quarterly report: Q3 2025 - Filings
- 10 months ago - IDL Diagnostics AB Quarterly report: Q2 2025 - Filings